83 related articles for article (PubMed ID: 19303535)
21. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
Wittmann T; Paradowski L; Ducrotté P; Bueno L; Andro Delestrain MC
Aliment Pharmacol Ther; 2010 Mar; 31(6):615-24. PubMed ID: 20003095
[TBL] [Abstract][Full Text] [Related]
22. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
23. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
24. Abdominal pain impacts quality of life in women with irritable bowel syndrome.
Cain KC; Headstrom P; Jarrett ME; Motzer SA; Park H; Burr RL; Surawicz CM; Heitkemper MM
Am J Gastroenterol; 2006 Jan; 101(1):124-32. PubMed ID: 16405544
[TBL] [Abstract][Full Text] [Related]
25. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
26. Impact of upper digestive symptoms in patients with irritable bowel syndrome.
Balboa A; Mearin F; Badía X; Benavent J; Caballero AM; Domínguez-Muñoz JE; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M;
Eur J Gastroenterol Hepatol; 2006 Dec; 18(12):1271-7. PubMed ID: 17099375
[TBL] [Abstract][Full Text] [Related]
27. The placebo response rate in irritable bowel syndrome and inflammatory bowel disease.
Sands BE
Dig Dis; 2009; 27 Suppl 1():68-75. PubMed ID: 20203499
[TBL] [Abstract][Full Text] [Related]
28. Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement.
Whitehead WE; Palsson OS; Levy RL; Feld AD; VonKorff M; Turner M
Am J Gastroenterol; 2006 May; 101(5):1057-65. PubMed ID: 16573774
[TBL] [Abstract][Full Text] [Related]
29. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
31. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome.
Camilleri M; Kim DY; McKinzie S; Kim HJ; Thomforde GM; Burton DD; Low PA; Zinsmeister AR
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):111-21. PubMed ID: 15017503
[TBL] [Abstract][Full Text] [Related]
32. Analyzing the content of outcome measures in clinical trials on irritable bowel syndrome using the international classification of functioning, disability and health as a reference.
Schönrich S; Brockow T; Franke T; Dembski R; Resch KL; Cieza A
Rehabilitation (Stuttg); 2006 Jun; 45(3):172-80. PubMed ID: 16755436
[TBL] [Abstract][Full Text] [Related]
33. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome.
Dumitraşcu DL; Stănculete M
Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
[TBL] [Abstract][Full Text] [Related]
35. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
Corsetti M; Tack J
Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of alverina citrate and simethicone combination in abdominal pain and discomfort of irritable bowel syndrome].
Wittmann T; Paradovsky L; Ducrotte P; Bueno L; Andro-Delestrain MC
Eksp Klin Gastroenterol; 2011; (3):60-7. PubMed ID: 21698811
[TBL] [Abstract][Full Text] [Related]
37. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.
Camilleri M; Mangel AW; Fehnel SE; Drossman DA; Mayer EA; Talley NJ
Clin Gastroenterol Hepatol; 2007 May; 5(5):534-40. PubMed ID: 17428741
[TBL] [Abstract][Full Text] [Related]
38. Adverse events appear to unblind clinical trials in irritable bowel syndrome.
Shah E; Triantafyllou K; Hana AA; Pimentel M
Neurogastroenterol Motil; 2014 Apr; 26(4):482-8. PubMed ID: 24350975
[TBL] [Abstract][Full Text] [Related]
39. How can we develop better antispasmodics for irritable bowel syndrome?
Ranjbar S; Seyednejad SA; Nikfar S; Rahimi R; Abdollahi M
Expert Opin Drug Discov; 2019 Jun; 14(6):549-562. PubMed ID: 30920313
[TBL] [Abstract][Full Text] [Related]
40. How positive and negative expectations shape the experience of visceral pain.
Elsenbruch S
Handb Exp Pharmacol; 2014; 225():97-119. PubMed ID: 25304528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
